Two-Carbon Linked Artemisinin Dimers for Malaria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antimalarial treatments face challenges due to parasite resistance and the limitations of artemisinin derivatives, such as poor bioavailability and short half-life, necessitating the development of new compounds with improved pharmacokinetic properties and mechanisms of action.
Innovation Solution
The development of two-carbon linked artemisinin-derived trioxane dimers, which are synthesized to enhance antimalarial efficacy and stability, and their use in combination with other antimalarial drugs to treat malaria and other parasitic infections, psychiatric conditions, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If artemisinin and its derivatives are used to treat malaria, then antimalarial efficacy is achieved, but bioavailability is poor and half-life is short
Solution Approach 1:
The patent combines two artemisinin units through a two-carbon linker to form a dimeric structure. This merging of two active units into one molecule increases the duration of action and half-life while maintaining antimalarial efficacy, directly resolving the contradiction between efficacy and duration of action
Solution Approach 2:
The invention creates a composite molecular structure by linking two artemisinin trioxane units through a two-carbon bridge. This composite dimeric structure exhibits improved pharmacokinetic properties including longer half-life and enhanced stability compared to monomeric artemisinin derivatives, while preserving the antimalarial activity
2Reliability
If artemisinin derivatives are used to treat malaria, then antimalarial activity is achieved, but parasite resistance develops
Solution Approach 1:
By combining two artemisinin units in a dimeric structure with a two-carbon linker, the patent creates a novel molecular entity with enhanced antimalarial activity. The dual active units provide synergistic effect and reduced susceptibility to parasite resistance mechanisms that have developed against monomeric artemisinin derivatives
3Ease of operation
If first generation artemisinin derivatives (artemether, artesunate) are used, then water or lipid solubility is improved, but metabolic liabilities remain and half-life is short
Solution Approach 1:
The patent merges two artemisinin units to form a dimer that overcomes the metabolic liabilities of first-generation derivatives. The dimeric structure with two-carbon linker provides enhanced stability and longer half-life while maintaining the solubility characteristics needed for pharmacological activity
Solution Approach 2:
The invention changes the molecular parameters by creating a dimeric structure with specific two-carbon linkage. This structural modification alters the pharmacokinetic parameters including half-life, stability, and metabolic resistance, while preserving the therapeutic efficacy and solubility properties
Data Source
AI summary
Two-carbon linked artemisinin-derived trioxane dimers and methods of their use for treating subjects infected with malaria or other parasitic infectious diseases including, but not limited to, toxoplasmic infection; subjects afflicted with psychiatric conditions associated with toxoplasmic infection; and subjects afflicted with cancer.